MANCHESTER, NH, June 25, 2024 /PRNewswire/ – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development and diagnostics, announced a strategic partnership with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematological malignancies. This collaboration uses the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clients, ultimately improving patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
Goals of the collaboration include:
- Data Access and AI Training: GTC will give BioAI access to characterized image data to train AI algorithms for product development and sponsored projects.
- Biomarker Development: Joint efforts will focus on developing genomic biomarker screening algorithms and assays, and deploying them in clinical settings.
- Comprehensive solutions: Customers will benefit from a suite of solutions that include screening tests and comprehensive genomic profiling using DNA and RNA for tissue and liquid biopsies.
Thomas ColarussoCEO of BioAI, said:
“BioAI is excited to partner with leaders in clinical laboratory services and diagnostics such as GTC to support the development, validation and future deployment of new AI-based tests. GTC is a perfect partner for us as they have a strong track record from developing and launching new clinical biomarker tests for primary care and supporting biopharma research and clinical trials to improve patient care and drive therapy decisions.”
Jeff OwenVice President, Marketing, said: “GTC is pleased to partner with BioAI, its digital pathology technology strengthens our product portfolio to pharmaceutical clients and will help us demonstrate the potential of our digital and molecular sample bank in the development of clinically useful comprehensive biomarkers .
We recognize that AI algorithms in digital pathology, combined with molecular profiling, will improve our ability to develop biomarkers that can be used by all pathologists.”
About BioAI
BioAI is a leading provider of multimodal AI for digital health in precision medicine, offering world-leading machine learning technology to develop digital biomarkers and H&E-based predictive models. They collaborate with leading pharmaceutical, biotechnology, clinical laboratories, and academic cancer centers around the world. With the PredictX platform, BioAI aims to revolutionize personalized medicine by improving drug effectiveness and patient outcomes. For more information about BioAI and its innovative machine learning technologies, visit https://bioaihealth.com.
About Genomic Testing Cooperative, LCA
Genomic Testing Cooperative (GTC) is a privately owned molecular testing company in Lake Forest, CA. The company operates on the basis of a cooperative (co-op) business model. Members of the cooperative hold type A shares with voting rights. The company offers its patron members a full suite of comprehensive genomic profiling based primarily on next generation sequencing. Molecular changes are identified based on rigorous testing using specially developed algorithms to increase accuracy and efficiency. The clinical relevance of the detected changes is extracted from different databases with internally developed software. Relevance of findings to diagnosis, prognosis, selecting therapy, and predicting outcome are reported to members. The co-op model allows GTC to make the test and information platform available to members at a lower cost due to a lower overhead. For more information you can visit https://genomictestingcooperative.com/
Forward Looking Statements
All statements, expectations and assumptions in this press release are forward-looking. Such forward-looking statements are based on the current expectations of GTC management and include statements regarding the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, therapy, the ability of tests to provide clinically useful information. All information in this press release is as of the date of release, and GTC undertakes no obligation to update this information, except as required by law.
Media contacts:
Ashlyn Alese
Director of Marketing
BioAI
Jeff Owen
VP, marketing
Genomic Testing Cooperative
SOURCE BioAI Health